Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In this Review, Kemper and colleagues discuss the canonical and non-canonical roles of the complement system in the pathogenesis of atherosclerosis and discuss potential new therapeutic strategies targeting the complement system for the prevention and treatment of atherosclerotic cardiovascular disease.
Patients with cardiovascular disease (CVD) have an increased risk of cancer, and patients with cancer have an increased risk of CVD. In this Review, the authors discuss the shared modifiable risk factors and the shared pathophysiological mechanisms underlying the bidirectional relationship between these two prevalent diseases.
In this Review, van Leent and colleagues provide an overview of current PET imaging approaches for assessment of atherosclerotic cardiovascular disease, as well as of whole-body PET applications; discuss the link between imaging readouts and atherosclerotic plaque pathology; and highlight promising developments in PET systems and radiotracer synthesis.
After myocardial infarction, the heart secretes small extracellular vesicles with pro-neoplastic properties that can accelerate tumour growth when taken up by cancer cells.
In ST-segment elevation myocardial infarction, the role of interventional modification of thrombi in the coronary arteries before stenting is controversial. However, innovations in stroke intervention have sparked renewed interest in thrombus modification approaches. We discuss current and emerging techniques to extract or disperse thrombi, aiming to reduce downstream embolization, microvascular obstruction and myocardial injury.
A new study identifies a hormone that is secreted by the gut in response to cholesterol absorption and can inhibit cholesterol synthesis in the liver, which prevents an increase in circulating cholesterol levels.
In this Review, Bozkurt provides an overview of the management of patients with heart failure across the full range of left ventricular ejection fraction, derived from the recommendations in the latest US and European guidelines.
In this Review, the authors address considerations for enteral antithrombotic therapy in patients with cardiovascular disease and gastrointestinal comorbidities, who often have an increased risk of gastrointestinal bleeding. Approaches include tailoring of antithrombotic regimens and gastrointestinal-protection strategies.
In patients with carotid artery disease, the presence of microplastics and nanoplastics in the carotid plaque is associated with an increased risk of death or major cardiovascular events compared with patients in whom microplastics and nanoplastics were not detected.
In this Tools of the Trade article, Trivett discusses the potential of long-read sequencing in generating high-quality reference genomes of animal models of cardiovascular disease.
Protein glycosylation is vital to the regulation of cell function, and changes in this post-translational modification underlie many disease processes. In this Review, Chatham and Patel discuss how protein glycosylation contributes to normal cardiovascular function and its role in cardiovascular disease, identifying important knowledge gaps and areas for future research.
Non-coding RNAs are implicated in the pathophysiology of ischaemic heart disease and heart failure. In this Review, Caporali and colleagues examine the biology of these molecules and discuss the potential of non-coding RNAs for translation to the clinic as biomarkers and therapeutics in adverse cardiac remodelling leading to ischaemic heart failure.
In this Tools of the Trade article, Charrière describes the FluoStep FRET-based biosensor used for high-resolution imaging of cAMP nanodomains that are involved in intracellular signalling in cardiomyocytes.
Novel cardiovascular therapeutics have the potential to improve health outcomes, but financial toxicity from high out-of-pocket costs can limit the reach of these medications and worsen existing health disparities. Understanding the phenomenon of financial toxicity in treating cardiovascular disease is crucial to achieving health equity.
In this Tools of the Trade article, Olivera describes a rat model of pre-elampsia that has been instrumental for investigating potential long-term cardiovascular effects in offspring.
A new approach to modify the epigenome can lead to durable silencing of Pcsk9 in mice, thereby reducing plasma LDL-cholesterol levels, according to a study published in Nature.
Shoaran and Maffia recount how our understanding of the role of inflammation in atherosclerosis has evolved and highlight the study by Göran Hansson and colleagues that provided the first hint of the involvement of the adaptive immune response in atherosclerosis.
